| $687M | ||
| $385M | ||
| $215M | ||
| $100M | ||
| $94M | ||
| $82M |
Buys | $ | – | |
Sells | $ | – |
Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, develops gene therapy product candidates to treat ocular and rare diseases. Its lead product candidate is ADVM-022, a single intravitreal injection gene therapy candidate used for the treatment of patients with chronic retinal, including wet age-related macular degeneration and diabetic macular edema. Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; Cornell University; GenSight; Lexeo; and Virovek. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was incorporated in 2006 and is headquartered in Redwood City, California.
Over the last 12 months, insiders at Adverum Biotechnologies, Inc. have bought $undefined and sold $undefined worth of Adverum Biotechnologies, Inc. stock.
On average, over the past 5 years, insiders at Adverum Biotechnologies, Inc. have bought $1.57M and sold $1.66M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 117,614 shares for transaction amount of $506,916 was made by Fischer Laurent (CEO, PRESIDENT AND DIRECTOR) on 2025‑12‑08.
| Increased Positions | 0 | 0% | 0 | 0% |
| Decreased Positions | 0 | 0% | 0 | 0% |
| New Positions | 0 | New | 0 | New |
| Sold Out Positions | 0 | Sold Out | 0 | Sold Out |
| Total Postitions | 0 | 0% | 0 | 0% |